Notice: 函数 WP_Styles::add 的调用方法不正确。 The style with the handle "storefront-woocommerce-style" was enqueued with dependencies that are not registered: storefront-style. 请查阅调试 WordPress来获取更多信息。 (这个消息是在 6.9.1 版本添加的。) in /wordpress/wp-includes/functions.php on line 6260

KC-4781

CHOK1-STEAP1-Cell-Line

Home » Cell Lines » CHOK1-STEAP1-Cell-Line

Background of CHOK1-STEAP1-Cell-Line

The STEAP family contains four members, named STEAP1–4, all of which have in common a six transmembrane domain with the COOH- and N-terminals located in the cytosol. STEAP1 was the first member of the STEAP family to be identified and has been widely studied as a gene related to cancer progression. STEAP1 was previously predicted not to promote iron and cooper reduction or uptake mainly due to the lack of the N-terminal NADPH-binding F420H2: NADP+ oxidoreductase domain unlike other STEAP members. However, a recent study revealed that STEAP1 exhibits cellular ferric reductase activity by fusing to the intracellular NADPH-binding domain of STEAP4. These findings can ultimately contribute to the development of STEAP1 targeted therapy. In contrast, the pathological functions of STEAP1 in cancer still need further investigation.

Specifications

Catalog Number:
KC-4781
Cell Line Name:
CHOK1-STEAP1-Cell-Line
Clone Number
Host Cell Line:
CHOK1
Description:
Stable CHOK1 clone expressing exogenous STEAP1 gene.
Quantity:
Two vials of frozen cells (2-5×106/vial)
Stability:
Stable in culture over a minimum of 10 passages
Application:
Drug screening and biological assays
Freezing Medium:
70% RPMI 1640 + 20% FBS + 10% DMSO
Propagation Medium:
RPMI 1640 + 10% FBS + 10μg/mL Puromycin
Selection Marker:
Puromycin
Morphology:
Epithelial
Subculture:
Split saturated culture 1:6-1:8 every 2-3 days; seed out at about 1-3 × 105 cells/mL
Incubation:
37 °C with 5% CO2
Storage:
Liquid nitrogen immediately upon receiving
Doubling Time:
Approximately 24 hours
Mycoplasma Status:
Negative
In Vivo Validation:

Cell Line Generation

CHOK1-STEAP1-cell-line was generated using a lentiviral vector expressing the STEAP1 sequence.

Characterization

Figure 1: Characterization of STEAP1 overexpression in the CHOK1-STEAP1 stable clone using FACS.

Figure 2: Characterization of STEAP1 overexpression in the STEAP1 stable clone using PCR.

Figure 3: Characterization of STEAP1 overexpression in the CHOK1-STEAP1 stable clone using FACS.

Cell Resuscitation

1. Prewarm culture medium (RPMI 1640 supplemented with 10% FBS and 10μg/mL puromycin)in a 37°C water bath.
2. Thaw the frozen vial in a 37°C water bath for 1-2 minutes.
3. Transfer the vial into biosafety cabinet, and wipe the surface with 70% ethanol.
4. Unscrew the top of the vial and transfer the cell suspension gently into a sterile centrifuge tube containing 9.0mL complete culture medium.
5. Spin at ~ 125 × g for 5-7 minutes at room temperature, and discard the supernatant without disturbing the pellet.
6. Resuspend cell pellet with the appropriate volume of complete medium and transfer the cell suspension into a T25 culture flask.
7. Incubate the flask at 37°C, 5% CO2 incubator.
8. Split saturated culture 1:6-1:8 every 2-3 days; seed out at about 1-3 × 105 cells/mL.

Cell Freezing

1. Prepare the freezing medium (70% RPMI 1640 + 20% FBS + 10% DMSO) fresh immediately before use.
2. Keep the freezing medium on ice and label cryovials.
3. Transfer cells to a sterile, conical centrifuge tube, and count the cells.
4. Centrifuge the cells at 250×g for 5 minutes at room temperature and carefully aspirate off the medium.
5. Resuspend the cells at a density of at least 3×106 cells/mL in chilled freezing medium.
6. Aliquot 1 mL of the cell suspension into each cryovial.
7. Freeze cells in the CoolCell freezing container overnight in a -80°C freezer.
8. Transfer vials to liquid nitrogen for long-term storage.

References

1.Bhatia, V., Kamat, N.V., Pariva, T.E. et al. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. Nat Commun 14, 2041 (2023).
2.Nakamura H, Arihara Y, Takada K. Targeting STEAP1 as an anticancer strategy. Front Oncol. 2023 Oct 16;13:1285661. doi: 10.3389/fonc.2023.1285661. PMID: 37909017; PMCID: PMC10613890.
3.Xu M, Evans L, Bizzaro CL, Quaglia F, Verrillo CE, Li L, Stieglmaier J, Schiewer MJ, Languino LR, Kelly WK. STEAP1-4 (Six-Transmembrane Epithelial Antigen of the Prostate 1-4) and Their Clinical Implications for Prostate Cancer. Cancers (Basel). 2022 Aug 20;14(16):4034. doi: 10.3390/cancers14164034. PMID: 36011027; PMCID: PMC9406800.